Posterior chamber collagen copolymer phakic intraocular lenses to correct myopia : five-year follow-up

Abstract

PURPOSE: To evaluate the long-term safety and efficacy of posterior chamber collagen copolymer phakic intraocular lens (pIOL) implantation to correct myopia. SETTING: Fern!andez-Vega Ophthalmological Institute, Oviedo, Spain. DESIGN: Cohort study. METHODS: Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, pIOL vault, endothelial cell loss, and adverse events were evaluated for 5 years after implantation of the Visian Implantable Collamer Lens pIOL for moderate to high myopia. RESULTS: The mean spherical equivalent (188 eyes) decreased from !11.17 diopters (D)G 3.40 (SD) preoperatively to!0.88G0.72 D 5 years postoperatively. The mean change in refraction from 1 month to 5 years was !0.65G0.65 D. The mean UDVA and CDVA (Snellen decimal) were 0.69G 0.26 and 0.83 G 0.15, respectively. The mean safety and efficacy indices were 1.27 G 0.33 and 0.89 G 0.35, respectively. No eye lost more than 2 lines of visual acuity; 70% achieved 0.80 or better CDVA. Three eyes (1.6%) developed late anterior subcapsular cataract that was clinically significant in 1 case, leading to pIOL removal and phacoemulsification. Of the 3 eyes (1.6%) with a mild transient increase in intraocular pressure (up to 27 mm Hg), none required a second surgical procedure or prolonged topical medication. The total endothelial cell loss (considered cumulatively at consecutive intervals through 5 years) was 7.7%. There was a tendency toward decreased pIOL vault decrease over time. No vision-threatening complications occurred. CONCLUSION: Implantation of the collagen copolymer pIOL for moderate to high myopia was safe and effective and provided long-term predictable, stable refractive results.